Clinical trial · no report yet · Phase 3

KEYNOTE-676 trial: what clinicians have said so far

Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676)

NCT03711032 ↗
Active, not recruiting
Merck Sharp & Dohme LLC
Deep size, estimated: 301+ verified statements once built

We haven't built an HCP commentary report on KEYNOTE-676 (pembrolizumab in high-risk non-muscle invasive bladder cancer) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.

Indexed commentary on KEYNOTE-676 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

Indexed so far
20 YouTube videos, typically up to 88 once built
19 posts on X, typically up to 84 once built
11 podcast episodes, typically up to 48 once built

Indexed todayTypical once built

The trial

ClinicalTrials.gov

Official title: A Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in Participants With High-risk Non-muscle Invasive Bladder Cancer (HR NMIBC) That is Either Persistent or Recurrent Following BCG Induction or That is Naïve to BCG Treatment (KEYNOTE-676)
Phase: Phase 3
Status: Active, not recruiting
Conditions: High-risk Non-muscle Invasive Bladder Cancer
Interventions: Pembrolizumab; BCG
Arms: BCG plus Pembrolizumab: Post-induction Cohort A (Arm A-1) · Experimental
BCG Monotherapy: Post-induction Cohort A (Arm A-2) · Experimental
BCG plus Pembrolizumab: BCG Naïve Cohort B-Reduced Maintenance (Arm B-1) · Experimental
BCG plus Pembrolizumab: BCG Naïve Cohort B-Full Maintenance (Arm B-2) · Experimental
BCG Monotherapy: BCG Naïve Cohort B (Arm B-3) · Experimental
Enrollment: 1,397 (estimated)
Primary outcomes: Complete Response Rate (CRR) by Blinded Independent Central Review (BICR) (Cohort A)
Event-Free Survival (EFS) (Cohort B)
Sponsor: Merck Sharp & Dohme LLC
Start: Dec 24, 2018
Primary completion: Jul 31, 2028 (estimated)
Results posted: No
Registry record: NCT03711032 · updated Oct 23, 2026

Publications

linked from the registry

Kamat AM, Shore N, Hahn N, Alanee S, Nishiyama H, Shariat S, Nam K, Kapadia E, Frenkl T, Steinberg G. KEYNOTE-676: Phase III study of BCG and pembrolizumab for persistent/recurrent high-risk NMIBC. Future Oncol. 2020 Apr;16(10):507-516. doi: 10.2217/fon-2019-0817. Epub 2020 Mar 12. PubMed 32162533

Get this report

Deep

Report, built on orderBuilt within 24 hours of confirming your order: $1,950

Order this report

Quoted on an estimate of the verified statements in the commentary we've indexed so far. Final coverage is set when we build it.You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded.We build it within 24 hours of confirming your order. If we can't build it to our standard, you aren't charged.

Request a free preview

Ask us to build this report. Once it's built, its free preview (summary, finding titles and coverage) is published on this page and we email you the link. The full report is sold separately. Use your work email; we'll send a link to confirm it.

For agents: .json · .md

Indexed commentary on KEYNOTE-676 so far

Reports on the same drug or indication

The trial

Publications